Nouvelle déclaration d'incident
No de la demande: 2017-7478
Numéro de référence du titulaire d'homologation: USA-BAYERBAH-2017-US0065904 (Report 451472)
Nom du titulaire (nom légal complet, aucune abbréviation): Bayer inc
Adresse: 2920 Matheson BLVD
Ville: Mississaugua
État: ON
Pays: Canada
Code postal /Zip: L5W5R6
Incident chez un animal domestique
Pays: UNITED STATES
État: PENNSYLVANIA
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. Inconnu
Nom du produit: Advantage II pipette size unknown
Autre (préciser)
Spot-onOui
Inconnu
Site: Animal / Usage sur un animal domestique
Inconnu
Propriétaire de l'animal
Dog / Chien
Labrador Retriever
1
Homme
Inconnu
Inconnu
Cutanée
>1 wk <=1 mo / > 1 sem < = 1 mois
>8 hrs <=24 hrs / > 8 h < = 24 h
Système
Unknown / Inconnu
Inconnu
Inconnu
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On approximately 01-Jan-2017, a male, Retriever - Labrador dog, of unknown signalment and condition, with no known concomitant medical conditions, was administered 1 tube of Advantage II (dog-unspecified) (Imidacloprid-Pyriproxyfen) via the topical route by the animal owner. On approximately 02-Jan-2017, the dog exhibited lethargy and nausea. On an unspecified date in 2017, post application, the dog died. No known necropsy was performed. Due to the sensitive nature of the communication, specific relevant event details were not obtained, nor will such be sought. The reason for the initial call was to discuss the perceived lack of efficacy of Seresto with another pet and not to report the death in this event. No further information is expected. This case is closed.
Mort
N - Unlikely Nausea is an unspecific sign and may have many potential causes. Sign is not expected after topical product use and oral product uptake was not witnessed. However, a reaction to accidentally ingested product cannot be excluded. Lethargy is unspecific and may be associated with nausea in this case. Death is not expected following appropriate topical product application as inconsistent with products pharmacological profile. Product has wide margin of safety. The oral LD50 in rat is 642 mg/kg BW. 20-fold overdosage tolerated by dogs without showing any side effect. Even owner does not believe product involvement as the reason for death as the initial call was to discuss the perceived lack of efficacy of other product with another pet and not to report the death in this event. However in this case low level of information (e.g. animal details, health status, medical history and necropsy are unknown) provided. Time to onset for initial signs is short and unknown for death. Overall, considering death as serious and leading sign, a product involvement is considered as unlikely.